Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices 14601 

Dated: March 20, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1508 Filed 3–27–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Technologies Relating to SH2 

Domain Binding Inhibitors and 

Inhibition of Cell Motility and 

Angiogenesis 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Patent Application 

No. 09/937,150, filed March 26, 2002, 

entitled ‘‘Phenylalanine Derivatives’’

[E–105–1999/0–US–07]; U.S. Patent 

Application No. 10/517,717, filed March 

17, 2005, entitled ‘‘SH2 Domain Binding 

Inhibitors’’ [E–262–2000/1–US–03]; U.S. 

Patent Application No. 10/944,699, filed 

September 17, 2004, entitled ‘‘SH2 

Domain Binding Inhibitors’’ [E–315–

2003/0–US–02]; PCT Patent Application 

PCT/US05/35246, filed September 30, 

2005, entitled ‘‘A New Approach 

Toward Macrocyclization of Peptides’’

[E–327–2004/0–PCT–02]; U.S. 

Provisional Patent Application No. 60/ 

867,307, filed November 27, 2006, 

entitled ‘‘Macrocyclic GRB2 SH2 

Domain Binding Inhibitors Prepared 

Using Achiral Alkenyl Amines’’ [E–

305–2006/0–US–01]; U.S. Patent 

6,977,241, issued December 20, 2005, 

entitled ‘‘SH2 Domain Binding 

Inhibitors’’ [E–262–2000/0–US–03]; U.S. 

Patent 7,132,392, issued November 11, 

2006, entitled ‘‘Inhibition of Cell 

Motility and Angiogenesis by Inhibitors 

of the GRB2 SH2 Domain’’ [E–265–

1999/0–US–07]; to Angion Biomedica 

Corporation, having a place of business 

in Manhasset, New York. The patent 

rights in these inventions have been 

assigned to the United States of 

America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to cancer 

and the modulation of angiogenesis in 

inflammatory disease. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before May 

29, 2007 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Adaku Nwachukwu, J.D., 

Technology Licensing Specialist, Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435–

5560; Facsimile: (301) 402–0220; E-mail: 

madua@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: These 

technologies relate to anti-cancer drugs 

that target the inhibition of specific 

enzymes in certain pathways that will 

interfere with a cell’s signal 

transduction processes. The current 

technologies include specific 

compounds that inhibit GRB2 SH2 

domain binding. In addition, the 

technologies relate to how these 

compounds may inhibit cell motility 

and angiogenesis. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR part 404.7. The 

prospective exclusive license may be 

granted unless within sixty (60) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: March 16, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–5674 Filed 3–27–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: The Catalytic Moiety of the 

Glucose-6-Phosphatase System: The 

Gene and Protein and Related 

Mutations 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an exclusive 

license worldwide to practice the 

invention embodied in U.S. Patent 

Number 5,460,942 issued October 24, 

1995 entitled, ‘‘The Catalytic Moiety of 

the Glucose-6-Phosphatase System: the 

Gene and Protein and Related 

Mutations’’ (HHS Ref. No. E–179–1993/ 

0–US–01) to GlyGenix, Inc., having a 

place of business in Cheshire, CT 06410. 

The contemplated exclusive license may 

be limited to the following field of use: 

an FDA-approvable human therapeutic 

for Glycogen Storage Disease Type Ia. 

The United States of America is the 

assignee of the patent rights in this 

invention. 

DATES: Only written comments and/or 

application for a license which are 

received by the NIH Office of 

Technology Transfer on or before May 

29, 2007 will be considered. 

ADDRESSES: Requests for a copy of the 

patent, inquiries, comments, and other 

materials relating to the contemplated 

license should be directed to: Tara L. 

Kirby, PhD, Technology Licensing 

Specialist, Office of Technology 

Transfer, National Institutes of Health, 

6011 Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

301–435–4426; Facsimile: 301–402–

0220; E-mail: kirbyt@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: Glycogen 

storage diseases result from at least 10 

different genetic defects in proteins 

required by glycogen metabolism. 

Glycogen storage disease Type Ia (GSD, 

also known as von Gierke disease) is 

defined as the deficiency of glucose-6- 

phosphatase (G–6–Pase) which is 

normally present in liver, kidney, and 

intestine. Glycogen storage disease Type 

la is inherited by one per 100,000 

people as an autosomal recessive trait 

and is usually manifested during the 

first twelve months of life by 

symptomatic hypoglycemia, or by the 

recognition of hepatomegaly. In 


sroberts on PROD1PC70 with NOTICES
14602 Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices 

addition, GSD type Ia can cause growth 

retardation, delayed adolescence, 

lacticacidemia, hyperlipidemia, 

hyperuricemia, and in adults, hepatic 

adenomas. 

The invention discloses nucleic acid 

sequences and vectors useful for 

producing recombinant G–6–Pase 

proteins, as well as nucleic acid 

sequences and kits for detecting a 

mutation in the G–6–Pase gene. 

The prospective exclusive license will 

be royalty-bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, the NIH receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: March 20, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–5672 Filed 3–27–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Bureau of Customs and Border 

Protection 

[CBP Dec. 07–11] 

Re-Accreditation of Core Laboratories, 

Inc., as a Commercial Laboratory 

AGENCY: Bureau of Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: Notice of re-accreditation of 

Core Laboratories, Inc. of Sulfur, 

Louisiana, as an accredited commercial 

laboratory. 

SUMMARY: Notice is hereby given that, 

pursuant to 19 CFR 151.12, Core 

Laboratories, Inc., 4025 Oak Lane, 

Sulfur, Louisiana 60665, has been reaccredited to test Petroleum and 

Petroleum Products entered under 

Chapters 17 and 29 of the Harmonized 

Tariff Schedule of the United States 

(HTSUS) for customs purposes, in 

accordance with the provisions of 19 

CFR 151.12. Anyone wishing to employ 

this entity to conduct laboratory 

analysis should request and receive 

written assurances from the entity that 

it is accredited or approved by the 

Bureau of Customs and Border 

Protection to conduct the specific test 

requested. Alternatively, inquiries 

regarding the specific tests this entity is 

accredited to perform may be directed to 

the Bureau of Customs and Border 

Protection by calling (202) 344–1060. 

The inquiry may also be sent to 

http://www.cbp.gov/xp/ cgov/import/ 

operations_support/labs_scientific_svcs/ 

org_and_operations.xml. 

DATES: The re-accreditation of Core 

Laboratories, Inc., as an accredited 

laboratory became effective on March 

23, 2005. The next triennial inspection 

date will be scheduled for March 2008. 

FOR FURTHER INFORMATION CONTACT: 

Eugene J. Bondoc, PhD, or Randall 

Breaux, Laboratories and Scientific 

Services, Bureau of Customs and Border 

Protection, 1300 Pennsylvania Avenue, 

NW., Suite 1500N, Washington, DC 

20229, 202–344–1060. 

Dated: March 22, 2007. 

Ira S. Reese, 

Executive Director, Laboratories and 

Scientific Services. 

[FR Doc. E7–5705 Filed 3–27–07; 8:45 am] 

BILLING CODE 9111–14–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Bureau of Customs and Border 

Protection 

[CBP Dec. 07–12] 

Re-Approval of the Strawn Group as a 

Commercial Gauger 

AGENCY: Bureau of Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: Notice of re-approval The 

Strawn Group of Houston, Texas, as a 

commercial gauger. 

SUMMARY: Notice is hereby given that, 

pursuant to 19 CFR 151.13, The Strawn 

Group, 3855 Villa Ridge, Houston, 

Texas 77068, has been re-approved to 

gauge petroleum and petroleum 

products, organic chemicals and 

vegetable oils for customs purposes, in 

accordance with the provisions of 19 

CFR 151.13. Anyone wishing to employ 

this entity for gauger services should 

request and receive written assurances 

from the entity that it is approved by the 

Bureau of Customs and Border 

Protection to conduct the specific 

gauger service requested. Alternatively, 

inquiries regarding the specific gauger 

services this entity is approved to 

perform may be directed to the Bureau 

of Customs and Border Protection by 

calling (202) 344–1060. The inquiry may 

also be sent to http://www.cbp.gov/xp/ 

cgov/import/operations_support/ 

labs_scientific_svcs/ 

org_and_operations.xml. 

DATES: The re-approval of The Strawn 

Group as a commercial gauger became 

effective on January 4, 2005. The next 

triennial inspection date will be 

scheduled for January 2008. 

FOR FURTHER INFORMATION CONTACT: 

Eugene J. Bondoc, PhD, or Randall 

Breaux, Laboratories and Scientific 

Services, Bureau of Customs and Border 

Protection, 1300 Pennsylvania Avenue, 

NW., Suite 1500N, Washington, DC 

20229, 202–344–1060. 

Dated: March 22, 2007. 

Ira S. Reese, 

Executive Director, Laboratories and 

Scientific Services. 

[FR Doc. E7–5706 Filed 3–27–07; 8:45 am] 

BILLING CODE 9111–14–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Bureau of Customs and Border 

Protection 

[CBP Dec. 07–13] 

Re-Accreditation and Re-Approval of 

Amspec Services as a Commercial 

Gauger and Laboratory 

AGENCY: Bureau of Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: Notice of re-approval of Amspec 

Services of Wilmington, North Carolina, 

as a commercial gauger and laboratory. 

SUMMARY: Notice is hereby given that, 

pursuant to 19 CFR 151.12 and 151.13, 

Amspec Services, 2841 Carolina Beach 

Road, Suite 3B, Wilmington, North 

Carolina 28412, has been re-approved to 

gauge petroleum and petroleum 

products, organic chemicals and 

vegetable oils, and to test petroleum and 

petroleum products for customs 

purposes, in accordance with the 

provisions of 19 CFR 151.12 and 151.13. 

Anyone wishing to employ this entity to 

conduct laboratory analysis or gauger 

services should request and receive 

written assurances from the entity that 

it is accredited or approved by the 

Bureau of Customs and Border 

Protection to conduct the specific test or 

gauger service requested. Alternatively, 


sroberts on PROD1PC70 with NOTICES